Shobu Watanabe MD, Presenter: Nothing to Disclose

Norihisa Nitta MD, Abstract Co-Author: Nothing to Disclose

Akinaga Sonoda MD, Abstract Co-Author: Nothing to Disclose

Keiko Tsuchiya, Abstract Co-Author: Nothing to Disclose

Ayumi N. Seko, Abstract Co-Author: Nothing to Disclose

Kiyoshi Murata MD, Abstract Co-Author: Nothing to Disclose

Hideji Otani MD, Abstract Co-Author: Nothing to Disclose

Toyohiko Tanaka MD, Abstract Co-Author: Nothing to Disclose

Miriplatin hydrate (miriplatin), which is a fat-soluble platinum complex, has the capability to be suspended in lipiodol. In this study, we evaluated anti-tumor effect of suspension of miriplatin-lipidol.

1. Cytotoxicity for 3 drugs (miriplatin suspended in lipiodol: ML, a soluble derivative of miriplatin: M and cisplatin: C). 2. 11 rabbits with VX2 liver tumor were randomly assigned to 3 groups. Group 1(G1): 4 animals with ML; Group 2(G2): 3 animals with cisplatin-lipiodol suspension (CL); and Group 3(G3): 4 animals with saline. All drugs were infused from proper hepatic artery. In all the groups, tumor growth rates were measured on MRI taken before and at 1 week of treatment.  3. Platinum concentrations (PCs) were determined in G1 and G2. Blood PCs were measured immediately after, at 10, 30, and 60 minutes, at 24 hours, and at 7 days of drug administration. PCs were also measured in the tumor tissues as well as in surrounding normal liver tissues at 7 days. Statistical analysis was conducted using Student’s t-test and Tukey’s HSD test.  

1. Miriplatin showed no cytotoxicity to VX2, whereas C did show significant cytotoxicity as well as M. However, miriplatin was found to be toxic to HeLa. C was proved significantly more toxic to both VX2 and HeLa than the other 2 drugs (p<0.05). 2. There was no significant difference between the growth rates of the tumor of G1 and G2 (p=0.84), while there were significant differences between G1 and G3 (p<0.05) and between G2 and G3 (p<0.05). 3. Blood PCs were below the detection level at any point of time after administration in G1, and were detected by 24 hours in G2. PCs in the tumor of G1 and G2 showed no significant differences at 7 days. (p=0.83) In the G1, PCs in the normal liver were significantly higher compared to those of G2 at 7 days. (p<0.05)

The anti-tumor effect of ML was confirmed. We found no significant difference between the anti-tumor effect of ML and CL at 1 week following administration.

Although further examination is needed regarding PCs in blood, tumors and normal tissues, ML and CL are effective treatments for hepatocellular carcinoma.

Watanabe, S, Nitta, N, Sonoda, A, Tsuchiya, K, Seko, A, Murata, K, Otani, H, Tanaka, T, Evaluation of Anti-tumor Effect of Miriplatin Hydrate-Lipiodol Suspension.  Radiological Society of North America 2010 Scientific Assembly and Annual Meeting, November 28 - December 3, 2010 ,Chicago IL. http://archive.rsna.org/2010/9007958.html